Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Ex vivo systems that incorporate features of the tumor microenvironment and model the dynamic response to immune checkpoint blockade (ICB) may facilitate efforts in precision immuno-oncology and the development of effective combination therapies. Here, we demonstrate the ability to interrogate ex vivo response to ICB using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS). MDOTS/PDOTS isolated from mouse and human tumors retain autologous lymphoid and myeloid cell populations and respond to ICB in short-term three-dimensional microfluidic culture. Response and resistance to ICB was recapitulated using MDOTS derived from established immunocompetent mouse tumor models. MDOTS profiling demonstrated that TBK1/IKKϵ inhibition enhanced response to PD-1 blockade, which effectively predicted tumor response in vivo. Systematic profiling of secreted cytokines in PDOTS captured key features associated with response and resistance to PD-1 blockade. Thus, MDOTS/PDOTS profiling represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens. Significance: Resistance to PD-1 blockade remains a challenge for many patients, and biomarkers to guide treatment are lacking. Here, we demonstrate feasibility of ex vivo profiling of PD-1 blockade to interrogate the tumor immune microenvironment, develop therapeutic combinations, and facilitate precision immuno-oncology efforts. Cancer Discov; 8(2); 196–215. ©2017 AACR. See related commentary by Balko and Sosman, p. 143. See related article by Deng et al., p. 216. This article is highlighted in the In This Issue feature, p. 127
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We did not observe an effect of IgG4 antibody control (Extended Data Fig. 2b), consistent with previous reports 14,19 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ex vivo profiling using murine-derived organotypic tumour spheroids (MDOTS) 14 derived from untreated mice bearing B16-ova tumours confirmed enhanced response to anti-PD-1 plus TBK1i (Fig. 1e).”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“and that disrupting TBK1 signaling has shown early promise enhancing response to ICB in murine tumour models 14,15 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Although reported sources of CCL19 and CXCL13 include stromal, immune, and tumor cells, a recent high-resolution study using single-cell RNA sequencing (RNA-seq) of melanoma specimens demonstrated CCL19 expression in cancer-associated fibroblasts (CAF) and CXCL13 with CD8+ exhausted T cells (46).”
BackgroundSelf-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 2×
“As PD-1 blockade promotes immune cell infiltration in vivo (13), we also performed singlesample gene set enrichment analysis (ssGSEA) using published immune signatures (37), which revealed enrichment of diverse immune cell populations in a subset of patients (group A) treated with ICB (Fig.”
Method
Research works printed but not linked: 1
- Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11. doi: 10.1126/science.aad0095. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
Cited by
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
“For MDOTS experiments, CT26GFP+cells (2x106) were subcutaneously injected into the right flank using a 27 g needle and tumors were harvested 14 days post transplantation.”
InfluentialSelf-citationOrganoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
“Alternatively, custom microfluidic devices with human tumor suspension-derived microspheroids containing immune cells exhibit response to immunotherapeutics, but without tumor-immune specificity (Deng et al., 2018; Jenkins et al., 2018).”
BackgroundMethodA Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Self-citationRobust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 738
Self-citationImproving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
“Accordingly, 3D glioblastoma chips using different molecular subtypes of patient-derived tumor cells [48] or organotypic tumor spheroids [74] were engineered to recapture patient tumor immunity, evaluate patientspecific responsiveness to anti-PD-1 immunotherapy, and screen for additional therapeutic combinations.”
BackgroundCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer
Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526
“In particular, although KRAS-TP53 (KP) lung tumors engage the PD-1/ PD-L1 immune checkpoint, KRAS-LKB1 (KL) tumors lack PD-L1 expression and fail to respond to immune checkpoint blockade (ICB; ref.”
BackgroundMethodInfluentialSelf-citationOrganoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K. P., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 479
“These organoids retained native immune cells [75,76].”
BackgroundPrediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
“Additionally, although ovarian organoid cultures contain a minimal stromal component and do not faithfully mimic all components of the tumor microenvironment, organoids do contain immune cells (20), and may be useful in studying the immune intereaction with the tumor in real time.”
BackgroundTumor organoid–T-cell coculture systems
Cattaneo, C. M., Dijkstra, K. K., Fanchi, L. F., Kelderman, S., Kaing, S., van Rooij, N., van den Brink, S., Schumacher, T. N., & Voest, E. E. (2020) · Nature Protocols · doi:10.1038/s41596-019-0232-9 · Cited by 410
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 402
“Blockade of TBK1/TKKε innate immune signaling kinases inhibited immunosuppressive cytokine production by CT26 tumor cells and enhanced cytotoxicity of the tumor in combination with PD-1 blockade [43].”
BackgroundMethodResultInfluentialDiskin, B., Adam, S., Cassini, M. F., Sanchez, G., Liria, M., Aykut, B., Buttar, C., Li, E., Sundberg, B., Salas, R. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0620-x · Cited by 392
Self-citationAn ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01398-3 · Cited by 380
Organoids in immunological research
Bar-Ephraim, Y. E., Kretzschmar, K., & Clevers, H. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0248-y · Cited by 361
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics
Borcherding, N., Vishwakarma, A., Voigt, A. P., Bellizzi, A., Kaplan, J., Nepple, K., Salem, A. K., Jenkins, R. W., Zakharia, Y., & Zhang, W. (2021) · Communications Biology · doi:10.1038/s42003-020-01625-6 · Cited by 364
Self-citationTreatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
Self-citationTumor organoids: Opportunities and challenges to guide precision medicine
Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339
Immunometabolic Interplay in the Tumor Microenvironment
Kaymak, I., Williams, K. S., Cantor, J. R., & Jones, R. G. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.09.004 · Cited by 328
“, 2019); c) organotypic tumor spheroids to identify associations between certain cytokines and chemokines and antitumor immunity (Jenkins et al., 2018); and d) co-culture of CRC-derived organoids with autologous TILs to predict cellular responses to chemoradiotherapy (Kong et al.”
BackgroundSelf-citationTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
“Accordingly, cultures from syngeneic immuno-competent mouse tumours and patient biopsies have been evaluated for 1–2 weeks within this system, modelling the TME and its dynamic responses to ICB 148–151 (Fig.”
InfluentialDefining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
“Within the USA, these efforts have tended to originate from the National Cancer Institute (NCI) Cancer Moonshot.”
InfluentialSelf-citationTumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Cañadas, I., Thummalapalli, R., Kim, J. W., Kitajima, S., Jenkins, R. W., Christensen, C. L., Campisi, M., Kuang, Y., Zhang, Y., Gjini, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0116-5 · Cited by 312
Self-citationCourau, T., Bonnereau, J., Chicoteau, J., Bottois, H., Remark, R., Assante Miranda, L., Toubert, A., Blery, M., Aparicio, T., Allez, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0553-9 · Cited by 274
Targeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Modeling neoplastic disease with spheroids and organoids
Zanoni, M., Cortesi, M., Zamagni, A., Arienti, C., Pignatta, S., & Tesei, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00931-0 · Cited by 261
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, A. R., Campisi, M., Ivanova, E., Portell, A., Larios, D., Piel, B. P., Mathur, N., Zhou, C., Coakley, R. V., Bartels, A., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00322j · Cited by 265
Self-citationChallenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine
Dijkstra, K. K., Monkhorst, K., Schipper, L. J., Hartemink, K. J., Smit, E. F., Kaing, S., de Groot, R., Wolkers, M. C., Clevers, H., Cuppen, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107588 · Cited by 254
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer
Wang, W., Marinis, J. M., Beal, A. M., Savadkar, S., Wu, Y., Khan, M., Taunk, P. S., Wu, N., Su, W., Wu, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.006 · Cited by 242
Self-citationPre-clinical modeling of cutaneous melanoma
Rebecca, V. W., Somasundaram, R., & Herlyn, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15546-9 · Cited by 228
Self-citationPatient-derived micro-organospheres enable clinical precision oncology
Ding, S., Hsu, C., Wang, Z., Natesh, N. R., Millen, R., Negrete, M., Giroux, N., Rivera, G. O., Dohlman, A., Bose, S., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.04.006 · Cited by 228
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26974-6 · Cited by 218
An expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
Li, F., Huang, Q., Luster, T. A., Hu, H., Zhang, H., Ng, W.-L., Khodadadi-Jamayran, A., Wang, W., Chen, T., Deng, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0780 · Cited by 203
“MDOTS was performed as previously described (68), and culture medium was harvested 3 days after treatment.”
MethodSelf-citationWan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 193
“Organoid co-cultures containing patient-matched tumor and all intratumoral immune cells represent a human model that can be studied over time using ICB treatments to ask questions about ICB efficacy and mechanism of action (17, 18).”
BackgroundCai, J., Song, L., Zhang, F., Wu, S., Zhu, G., Zhang, P., Chen, S., Du, J., Wang, B., Cai, Y., et al. (2024) · Cancer Communications · doi:10.1002/cac2.12607 · Cited by 179
“PDOTS were prepared and cultured following the methodology outlined by Jenkins et al. [37].”
An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity
Jiang, S., Zhao, H., Zhang, W., Wang, J., Liu, Y., Cao, Y., Zheng, H., Hu, Z., Wang, S., Zhu, Y., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100161 · Cited by 188
“Recapitulation of personalized immune responses to immunocheckpoint drugs targeting PD-1/PD-L1 has also been technically proven in organoids.(14,15) However, the current organoid technologies have limitations.”
BackgroundNguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
Zhou, Z., Cong, L., & Cong, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762184 · Cited by 178
“Patient-derived organotypic tumor spheroids can be generated and evaluated within one to two weeks (69, 77, 78).”
BackgroundCapasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J. R., Kopetz, S., Barbee, J., Peterson, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0518-z · Cited by 180
3D Tumor Models and Their Use for the Testing of Immunotherapies
Boucherit, N., Gorvel, L., & Olive, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.603640 · Cited by 171
Targeting TBK1 to overcome resistance to cancer immunotherapy
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174
Self-citationPatient-derived organoids in precision cancer medicine
Tong, L., Cui, W., Zhang, B., Fonseca, P., Zhao, Q. C., Zhang, P., Xu, B., Zhang, Q., Li, Z., Seashore-Ludlow, B. A., et al. (2024) · Med · doi:10.1016/j.medj.2024.08.010 · Cited by 208
Type I interferon signaling, regulation and gene stimulation in chronic virus infection
Lukhele, S., Boukhaled, G. M., & Brooks, D. G. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.05.001 · Cited by 165
Cui, X., Ma, C., Vasudevaraja, V., Serrano, J., Tong, J., Peng, Y., Delorenzo, M., Shen, G., Frenster, J., Morales, R.-T. T., et al. (2020) · eLife · doi:10.7554/elife.52253 · Cited by 163
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease
Aykut, B., Chen, R., Kim, J. I., Wu, D., Shadaloey, S. A. A., Abengozar, R., Preiss, P., Saxena, A., Pushalkar, S., Leinwand, J., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abb5168 · Cited by 154
Self-citationThe role of TBK1 in cancer pathogenesis and anticancer immunity
Runde, A. P., Mack, R. M., Breslin, P., & Zhang, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02352-y · Cited by 172
“This was supported further by another study that demonstrated that the loss of Tbk1 significantly enhanced the antineoplastic effect of PD-1 blockade in melanomas and in other models of malignancy [244].”
ResultHypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications
Shi, R., Liao, C., & Zhang, Q. (2021) · Cells · doi:10.3390/cells10030678 · Cited by 145
Patient-Derived Organoids for Precision Cancer Immunotherapy
Grönholm, M., Feodoroff, M., Antignani, G., Martins, B., Hamdan, F., & Cerullo, V. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4026 · Cited by 146
“In another study, murine- and patient-derived organotypic tumor spheroids cultured in a collagen matrix for up to 9 days in a microfluidics device were able to retain autologous lymphoid and myeloid cell populations (22).”
BackgroundMethodCell Culture in Microfluidic Droplets
Sart, S., Ronteix, G., Jain, S., Amselem, G., & Baroud, C. N. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00666 · Cited by 157
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Sanmamed, M. F., Nie, X., Desai, S. S., Villaroel-Espindola, F., Badri, T., Zhao, D., Kim, A. W., Ji, L., Zhang, T., Quinlan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0962 · Cited by 138
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
Sharick, J. T., Walsh, C. M., Sprackling, C. M., Pasch, C. A., Pham, D. L., Esbona, K., Choudhary, A., Garcia-Valera, R., Burkard, M. E., McGregor, S. M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00553 · Cited by 142
“Organoid cultures also preserve interactions between tumor cells, immune cells (10), and fibroblasts (11), which can influence tumor drug response and are potential drug targets (12, 13).”
BackgroundSenescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Harane, S. E., Zidi, B., Harane, N. E., Krause, K., Matthes, T., & Preynat‐Seauve, O. (2023) · Cells · doi:10.3390/cells12071001 · Cited by 154
“immune cells from explanted tumors [193,194].”
BackgroundZheng, H., Liu, J., Cheng, Q., Zhang, Q., Zhang, Y., Jiang, L., Huang, Y., Li, W., Zhao, Y., Chen, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00715-8 · Cited by 152
RetractedThe link between kidney disease and cancer: complications and treatment
Małyszko, J., Tesařová, P., Capasso, G., & Capasso, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30540-7 · Cited by 149
Tumor-on-chip modeling of organ-specific cancer and metastasis
Del Piccolo, N., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 126
Applications of tumor chip technology
Hachey, S. J., & Hughes, C. C. W. (2018) · Lab on a Chip · doi:10.1039/c8lc00330k · Cited by 128
Rashidian, M., LaFleur, M. W., Verschoor, V. L., Dongre, A., Zhang, Y., Nguyen, T. H., Kolifrath, S., Aref, A. R., Lau, C. J., Paweletz, C. P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905005116 · Cited by 129
“These closely model the microenvironment of the tumor in vivo (20, 21).”
BackgroundSelf-citationResearch Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Huang, Y., Huang, Z., Tang, Z., Chen, Y., Huang, M., Liu, H., Huang, W., Ye, Q., & Jia, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740574 · Cited by 124
“, 2018) or 3D microfluidic culture system (Jenkins et al., 2018), and the results showed that tumor spheres retain the original autologous matrix, related immune checkpoint deletion, tumor-infiltrating lymphoids, and myeloid subsets.”
BackgroundSelf-citationAdvances in Spheroids and Organoids on a Chip
Fang, G., Chen, Y., Lu, H., & Jin, D. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202215043 · Cited by 141
Wehrli, M., Guinn, S. R., Birocchi, F., Kuo, A., Sun, Y., Larson, R. C., Almazan, A. J., Scarfò, I., Bouffard, A. A., Bailey, S. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3841 · Cited by 141
Self-citationReview of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Alturki, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134301 · Cited by 135
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Functional precision oncology using patient-derived assays: bridging genotype and phenotype
van Renterghem, A. W. J., van de Haar, J., & Voest, E. E. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00745-2 · Cited by 132
3D Bioprinting of Tumor Models for Cancer Research
Kang, Y., Datta, P., Shanmughapriya, S., & Ozbolat, I. T. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00791 · Cited by 112
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Modugno, F. D., Colosi, C., Trono, P., Antonacci, G., Ruocco, G., & Nisticò, P. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1086-2 · Cited by 121
“This ex vivo functional immune profiling recapitulates key features of in vivo response and resistance to ICB and could represent a useful tool in the identification of biomarkers of ICB treatment response and, as the Authors reported, in the exploration of novel therapeutic combinations to enhance response to PD-1 bl…”
Ko, J., Wilkovitsch, M., Oh, J., Köhler, R. H., Bolli, E., Pittet, M. J., Vinegoni, C., Sykes, D. B., Mikula, H., Weissleder, R., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01339-6 · Cited by 121
Zhang, J., Tavakoli, H., Ma, L., Li, X., Han, L., & Li, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114365 · Cited by 114
TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss
Hu, L., Xie, H., Liu, X., Potjewyd, F., James, L. I., Wilkerson, E. M., Herring, L. E., Xie, L., Chen, X., Cabrera, J. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0837 · Cited by 108
“It is worth mentioning that the protein levels and phosphorylation state of IKKε, a close family member of TBK1, was not affected by VHL in these cells (Fig.”
InfluentialActivation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Chen, P.-H., Lipschitz, M., Weirather, J. L., Jacobson, C., Armand, P., Wright, K., Hodi, F. S., Roberts, Z. J., Sievers, S. A., Rossi, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134612 · Cited by 107
Self-citationA multiplexed microfluidic system for evaluation of dynamics of immune–tumor interactions
Moore, N., Doty, D., Zielstorff, M., Kariv, I., Moy, L. Y., Gimbel, A., Chevillet, J. R., Lowry, N., Santos, J., Mott, V., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00256h · Cited by 104
Modeling Cell Communication in Cancer With Organoids: Making the Complex Simple
Fiorini, E., Veghini, L., & Corbo, V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00166 · Cited by 117
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity
Wu, M., Kondo, H., Kammula, A. V., Shi, L., Xiao, Y., Dhiab, S., Xu, Q., Slater, C. J., Avila, O. I., Merritt, J., et al. (2024) · Science · doi:10.1126/science.adl6173 · Cited by 117
“Murine-derived organotypic tumor spheroids (MDOTS) were prepared and cultured as previously described ( 76 ).”
MethodSelf-citationAdvanced model systems and tools for basic and translational human immunology
Wagar, L. E., DiFazio, R. M., & Davis, M. M. (2018) · Genome Medicine · doi:10.1186/s13073-018-0584-8 · Cited by 102
The Use of Stem Cell-Derived Organoids in Disease Modeling: An Update
Azar, J., Bahmad, H. F., Daher, D., Moubarak, M. M., Hadadeh, O., Monzer, A., Al Bitar, S., Jamal, M., Al-Sayegh, M., & Abou-Kheir, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147667 · Cited by 96
“This would significantly help in dissecting the tumor microenvironment, enhancing precision immune-oncologic therapies, and ultimately deciphering the mechanisms behind immune checkpoint blockade resistance [9].”
BackgroundKong, J. C. H., Guerra, G. R., Millen, R. M., Roth, S., Xu, H., Neeson, P. J., Darcy, P. K., Kershaw, M. H., Sampurno, S., Malaterre, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00075 · Cited by 96
The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture
Blasio, S. D., van Wigcheren, G. F., Becker, A. M. D., van Duffelen, A., Gorris, M. A. J., Verrijp, K. N., Stefanini, I., Bakker, G., Bloemendal, M., Halilović, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16583-0 · Cited by 113
Patient-derived melanoma organoid models facilitate the assessment of immunotherapies
Ou, L., Liu, S., Wang, H., Guo, Y., Guan, L., Shen, L., Luo, R., Elder, D. E., Huang, A. C. C., Karakousis, G. C., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104614 · Cited by 108
Self-citationTosca, E. M., Ronchi, D., Facciolo, D., & Magni, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041058 · Cited by 103
3D cancer models: One step closer to in vitro human studies
Manduca, N., Maccafeo, E., Maria, R. D., Sistigu, A., & Musella, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175503 · Cited by 110
Harris, P. A., Marinis, J. M., Lich, J. D., Berger, S. B., Chirala, A., Cox, J. A., Eidam, P. M., Finger, J. N., Gough, P. J., Jeong, J. U., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00108 · Cited by 100
Du, Y., Wang, Y., Bao, Q., Xu, X., Xu, C., Wang, S., Liu, Q., Liu, F., Zeng, Y., Wang, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202412815 · Cited by 112
Engineering approaches for studying immune-tumor cell interactions and immunotherapy
Shelton, S. E., Nguyen, H. T., Barbie, D. A., & Kamm, R. D. (2021) · iScience · doi:10.1016/j.isci.2020.101985 · Cited by 93
“Studies in ex vivo murine organotypic models (Figures 4D–4F) have demonstrated that they can recapitulate in vivo drug sensitivities, lending credibility for performing similar studies with human organotypic models (Jenkins et al., 2018).”
BackgroundInfluentialSelf-citationBase editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 103
Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02505-w · Cited by 118
“Jenkins RW, et al. developed murine-and patient-derived organotypic tumour spheroids (MDOTS/PDOTS) to evaluate immune checkpoint blockade (ICB) responses [71].”
Activation of Tumor-Cell STING Primes NK-Cell Therapy
Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0017 · Cited by 88
Self-citationMultiplexed drug testing of tumor slices using a microfluidic platform
Horowitz, L. F., Rodriguez, A. D., Dereli-Korkut, Z., Lin, R., Castro, K., Mikheev, A. M., Monnat, R. J., Folch, A., & Rostomily, R. C. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0117-y · Cited by 88
Organoid Models for Precision Cancer Immunotherapy
Sun, C., Lan, H., Fang, X., Yang, X., & Jin, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.770465 · Cited by 107
Zhu, J., Ji, L., Chen, Y., Li, H., Huang, M., Dai, Z., Wang, J., Xiang, D., Fu, G., Lei, Z., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01354-9 · Cited by 95
“Currently, preclinical models like organoids and organs-on-chips show great potential in anticancer-drug screening, personalized therapy, and drug response prediction associated with patient outcomes [66, 67].”
BackgroundInfluentialIntegrated cancer tissue engineering models for precision medicine
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S., Snyder, C. S., & Mehta, G. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216564 · Cited by 82
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 93
Domblides, C., Rochefort, J., Riffard, C., Panouillot, M., Lescaille, G., Teillaud, J., Mateo, V., & Dieu‐Nosjean, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698604 · Cited by 88
“Murine and patient-derived organotypic tumor spheroids (termed MDOTS and HDOTS, respectively) loaded into 3D microfluidic devices containing immune cells have been developed in an effort to incorporate characteristics of TME and evaluate the response to ICP blockade (105).”
BackgroundNewly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 103
“The drug efficacy was further confirmed in in vivo models [46, 47].”
BackgroundSelf-citationImmunotherapy for small cell lung cancer: mechanisms of resistance
Hamilton, G., & Rath, B. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1592155 · Cited by 87
“to study ex vivo the response to IC inhibitors in short-term 3D microfluidic culture [69].”
Background3D Culture Systems for Exploring Cancer Immunology
Fitzgerald, A. A., Li, E., & Weiner, L. M. (2020) · Cancers · doi:10.3390/cancers13010056 · Cited by 91
“demonstrated tumor pieces derived from both murine and human tumors embedded in collagen containing 3D microfluidic chips—termed “organotypic tumor spheroids”—continue to grow and maintain immune cell composition [81].”
BackgroundCircadian regulator CLOCK promotes tumor angiogenesis in glioblastoma
Pang, L., Dunterman, M., Xuan, W., Gonzalez, A. M., Lin, Y., Hsu, W.-H., Khan, F., Hagan, R. S., Müller, W. A., Heimberger, A. B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112127 · Cited by 86
Immune organoids: from tumor modeling to precision oncology
Dao, V. A., Yuki, K., Lo, Y., Nakano, M., & Kuo, C. J. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.001 · Cited by 84
Metadata
- Authors
- Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., He, M. X., Walker, W., Zhang, G., Tian, T., Cheng, C., Wei, Z., Palakurthi, S., Bittinger, M., Vitzthum, H., Kim, J. W., Merlino, A., Quinn, M., Venkataramani, C., Kaplan, J. A., Portell, A., Gokhale, P. C., Phillips, B., Smart, A., Rotem, A., Jones, R. E., Keogh, L., Anguiano, M., Stapleton, L., Jia, Z., Barzily-Rokni, M., Cañadas, I., Thai, T. C., Hammond, M. R., Vlahos, R., Wang, E. S., Zhang, H., Li, S., Hanna, G. J., Huang, W., Hoang, M. P., Piris, A., Eliane, J.-P., Stemmer-Rachamimov, A. O., Cameron, L., Su, M.-J., Shah, P., Izar, B., Thakuria, M., LeBoeuf, N. R., Rabinowits, G., Gunda, V., Parangi, S., Cleary, J. M., Miller, B. C., Kitajima, S., Thummalapalli, R., Miao, B., Barbie, T. U., Sivathanu, V., Wong, J., Richards, W. G., Bueno, R., Yoon, C. H., Miret, J., Herlyn, M., Garraway, L. A., Van Allen, E. M., Freeman, G. J., Kirschmeier, P. T., Lorch, J. H., Ott, P. A., Hodi, F. S., Flaherty, K. T., Kamm, R. D., Boland, G. M., Wong, K.-K., Dornan, D., Paweletz, C. P., & Barbie, D. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Broad Institute (US)
- The Wistar Institute (US)
- New Jersey Institute of Technology (US)
- 11Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
- Brigham and Women's Hospital (US)
- Massachusetts Institute of Technology (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Corresponding author
- Dornan, David
- Barbie, David A.
- ORCID
- Jenkins, Russell W.
- Aref, Amir R.
- Lizotte, Patrick H.
- Ivanova, Elena
- Zhou, Chensheng W.
- Bowden, Michaela
- Deng, Jiehui
- Liu, Hongye
- Miao, Diana
- He, Meng Xiao
- Zhang, Gao
- Tian, Tian
- Cheng, Chaoran
- Wei, Zhi
- Palakurthi, Sangeetha
- Portell, Andrew
- Gokhale, Prafulla C.
- Smart, Alicia
- Rotem, Asaf
- Jones, Robert E.
- Keogh, Lauren
- Jia, Zhiheng
- Barzily-Rokni, Michal
- Cañadas, Israel
- Thai, Tran C.
- Wang, Eric S.
- Zhang, Hua
- Li, Shuai
- Hanna, Glenn J.
- Huang, Wei
- Hoang, Mai P.
- Piris, Adriano
- Stemmer-Rachamimov, Anat O.
- Cameron, Lisa
- Shah, Parin
- Izar, Benjamin
- Thakuria, Manisha
- LeBoeuf, Nicole R.
- Rabinowits, Guilherme
- Parangi, Sareh
- Cleary, James M.
- Miller, Brian C.
- Kitajima, Shunsuke
- Thummalapalli, Rohit
- Barbie, Thanh U.
- Wong, Joshua
- Richards, William G.
- Bueno, Raphael
- Yoon, Charles H.
- Miret, Juan
- Herlyn, Meenhard
- Garraway, Levi A.
- Freeman, Gordon J.
- Lorch, Jochen H.
- Ott, Patrick A.
- Hodi, F. Stephen
- Flaherty, Keith T.
- Kamm, Roger D.
- Boland, Genevieve M.
- Wong, Kwok-Kin
- Paweletz, Cloud Peter
- Barbie, David A.
- Venue
- Cancer Discovery
- Published
- 2018-02-01
- Volume
- 8
- Issue
- 2
- Pages
- 196-215
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5809290
- OpenAlex
- W2766123339
- Cited by
- 594
- References
- 62
- Citations by year
- 2026: 67 · 2025: 76 · 2024: 91 · 2023: 73 · 2022: 76 · 2021: 73 · 2020: 72 · 2019: 37 · 2018: 28
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (NCI) (NCI T32 CA009172-41, 1R01CA149738-01, NCI-R01 CA190394-01, P01CA120964, 5R01CA163896-04, 5R01CA140594-07, 5R01CA122794-10, 5R01CA166480-04)
- SU2C (SU2C-AACR-DT17-15)
- HHS | NIH | National Institute of General Medical Sciences (NIGMS) (NIGMS T32 GM008313)
- National Science Foundation (NSF) (NSF GRFP DGE1144152)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor microenvironment, immunotherapy resistance, cytokine production, precision immuno-oncology, combination therapy, microfluidic culture, patient-derived tumor models
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Flow Cytometry, Humans, Immunohistochemistry, Tumor Cells, Cultured, Immunophenotyping, Cytokines, Spheroids, Cellular, Cell Culture Techniques, Drug Resistance, Neoplasm, Cell Line, Tumor, Microfluidic Analytical Techniques, Mice, Time-Lapse Imaging, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.